Tony's Diary Package — page 891

Fast Company magazine activity attempting to control virus which has made its way from the upper airway to the lung. Sometimes this attempt to control the virus leads to so many inflammatory mediators combining innate with adaptive immune responses that the effects is a profound pathogenic response that may or may not be suppressed by anti-inflammatories and immune suppressors. A group of non USA scientists and others Whom I have never heard of Are trying to get rid of Peter Daszak at ecohealth . See PDF of letter immediately below : Letter to Nancye Green.pdf I do not know who these people are but something strange is going on here. I met with Leslie Dach at my home this evening to discuss the situation of attacks upon me by far-right elements. I gave to Leslie some reprints of papers that strongly favor the natural origin of COVID. We discussed strategies of how to stay ahead of this insidious campaign to discredit me. We feel that the best approach would be to lay low and not give it any more legs than it has. In addition, Leslie spoke to me about how pleased he was about how I have mentored Rochelle Walensky. He also expressed concern about her lack of leadership capabilities and her total dependence upon professionals at CDC who Leslie feels are antiquated in their thinking and in many respects are often incorrect. He referred to the experience he had with them when he was special advisor to Sylvia Burwell when Sylvia was Secretary of HHS. Leslie understandably has very little respect for the CDC and in fact wants me to help to get Rochelle to start thinking for herself instead of depending so heavily upon her CDC team. Leslie also expressed some concern about the lack of involvement of Secretary Becerra in the entire COVID effort. PRESS: Interview with Fast Company magazine Oct. 1, 2021 - GLOBAL USA We have reached 700,000 deaths in the USA!! Big anti-viral drug advance. Merck (Ridgeback) drug - Molnuvirapir (an RNA-dependent RNA polymerase inhibitor by inducing mistakes in the virus replication. The CEO of Merck Ron Davis briefed us last about the results. They were striking. In a study looking at people with documented mild to moderate infection not requiring hospitalization at the time within five days of diagnosis were given either placebo or drug. In the placebo group there were 53 hospitalizations in the drug group there were 28 hospitalizations with a 7.3% hospitalization in the drug group and 14.1% hospitalization in the placebo group. This led to a 50% efficacy with a P value of 0.001. There were eight deaths in the placebo group and zero deaths in the treatment group. This is really a major breakthrough in that it is another antiviral drug together with